News &amp; Updates

Discrimination exposure during adolescence may affect the neural response to future stressors, particularly within regions associated with emotion expression and regulation. As a result, this may alter the individual’s vulnerability and resilience to psychological distress, suggests a study.

Adolescent discrimination exposure ups risk of psychological distress

Lipoprotein(a)-lowering with zerlasiran succeeds in phase II trial

The small-interfering RNA zerlasiran appears promising in the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), reducing time time-averaged lipoprotein(a) concentration by more than 80 percent over 36 weeks of follow-up, as shown in a phase II trial.

Lipoprotein(a)-lowering with zerlasiran succeeds in phase II trial

Child abuse, psychiatric symptoms predict homelessness

Psychiatric symptoms earlier in life among individuals with a recorded history of childhood maltreatment appear to increase the risk of homelessness, which is considered a serious and increasing public health concern, suggests a recent study.

Child abuse, psychiatric symptoms predict homelessness

Retifanlimab plus chemo improves survival in metastatic NSCLC

The addition of retifanlimab to platinum-based chemotherapy results in better overall survival in patients with metastatic nonsmall cell lung cancer (NSCLC), as shown in the phase III study POD1UM-304 presented at ESMO Asia 2024. Moreover, the combination treatment has a safety profile consistent with that of other checkpoint inhibitors.

Retifanlimab plus chemo improves survival in metastatic NSCLC

07 Jan 2025

Photosensitivity status in atopic dermatitis may change over time

Light sensitivity patterns vary in patients with atopic dermatitis (AD), reports a Scotland study, noting the significance of follow-up assessments because of potential shifts in disease spectrum over time.

Photosensitivity status in atopic dermatitis may change over time

07 Jan 2025

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

07 Jan 2025

Vortioxetine improves overall mood state of cannabis users

Vortioxetine may help cannabis users improve their clinician-observed overall mood state, a pilot study has shown.

Vortioxetine improves overall mood state of cannabis users

Big data support clozapine’s safety: Rare incidence of blood cancer

An analytic cohort study in Hong Kong has shown that clozapine is associated with a rare but two-fold increased rate of haematological malignancy. Special warnings or more restrictive indications for its use may not be necessary.

Big data support clozapine’s safety: Rare incidence of blood cancer

Original New Drug Application Approvals by US FDA (16-31 December 2024)

New drug applications approved by US FDA as of 16-31 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 December 2024)

Mavacamten obviates long-term need for invasive septal reduction therapy in obstructive HCM

Treatment with the allosteric cardiac myosin inhibitor mavacamten in severely symptomatic patients with obstructive HCM allows for the deferral of invasive SRT for nearly 2.5 years, as shown in the end-of-trial results of VALOR-HCM presented at AHA 2024

Mavacamten obviates long-term need for invasive septal reduction therapy in obstructive HCM